uniQure is engaged in the development and commercialization of gene therapies for the treatment of cardiovascular and hemophilia diseases.
Business Model:
Revenue: $61.4M
Employees: 201-500
Address: Paasheuvelweg 25
City: Amsterdam
State: noord-holland
Zip: 1105BP
Country: NL
uniQure is engaged in the development and commercialization of gene therapies for the treatment of cardiovascular and hemophilia diseases.
Contact Phone:
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
2/6/2014
IPO Valuation:
$235M
Ticker Symbol:
QURE
IPO Price:
$29.5/share
Amount Raised:
$89M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 7/2014 | Post-IPO Debt | 1 | $20M |
Hercules Capital Hercules Capital |
4/2015 | Post-IPO Equity | $89M | 2/2014 | IPO | $91.8M |
|
5/2013 | Debt | $18.3M |
Coller Capital Forbion Capital Partners Gilde Healthcare Lupus Alpha |
8/2015 | Equity | $53M |
Bristol-Myers Squibb Company |
7/2013 | Private Equity Round | $0 |
Forbion Capital Partners Chiesi Pharmaceuticals Coller Capital Coller Capital Forbion Capital Partners Chiesi Pharmaceuticals Coller Capital Coller Capital |
7/2013 | Private Equity Round | 3 | $58M |
Forbion Capital Partners Chiesi Pharmaceuticals Coller Capital Coller Capital Forbion Capital Partners Chiesi Pharmaceuticals Coller Capital Coller Capital |
---|
Announced Date | Name | Price |
---|---|---|
6/2021 | Corlieve Therapeutics | |
8/2014 | InoCard |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|